WXXWY:OTC-WuXi Biologics (Cayman) Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.54

Change

0.00 (0.00)%

Market Cap

USD 7.17B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 598.54B
CSLLY CSL Ltd

N/A

USD 91.15B
CMXHF CSL Limited

N/A

USD 88.48B
UCBJF UCB SA

N/A

USD 26.91B
UCBJY UCB SA ADR

N/A

USD 26.37B
ARGNF argenx SE

N/A

USD 22.41B
GNMSF Genmab A/S

N/A

USD 17.89B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.83B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B

ETFs Containing WXXWY

3182:HK W.I.S.E-Nasdaq Overseas C.. 2.91 % 0.00 %

N/A

N/A
CN Xtrackers MSCI All China .. 0.00 % 0.28 %

N/A

USD 5.93M
EEMO Invesco S&P Emerging Mark.. 0.00 % 0.27 %

N/A

USD 7.93M
FXI iShares China Large-Cap E.. 0.00 % 0.74 %

N/A

USD 4.85B
MCHI iShares MSCI China ETF 0.00 % 0.59 %

N/A

USD 5.75B
EMSG DBX ETF Trust - Xtrackers.. 0.00 % 0.00 %

N/A

USD 0.03B
CHIL 0.00 % 0.00 %

N/A

N/A
CEA1:LSE iShares VII Public Limite.. 0.00 % 0.00 %

N/A

USD 2.47B
DBRC:LSE iShares BRIC 50 UCITS 0.00 % 0.00 %

N/A

USD 0.11B
EIMU:LSE iShares Core MSCI EM IMI .. 0.00 % 0.00 %

N/A

USD 1.28B
FXC:LSE iShares China Large Cap U.. 0.00 % 0.00 %

N/A

USD 0.66B
HMAD:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

N/A

USD 0.15B
HMCD:LSE HSBC MSCI China UCITS ETF 0.00 % 0.00 %

N/A

USD 0.62B
HMFE:LSE 0.00 % 0.00 %

N/A

N/A
IDFX:LSE iShares China Large Cap U.. 0.00 % 0.00 %

N/A

USD 0.66B
IEEM:LSE iShares MSCI Emerging Mar.. 0.00 % 0.00 %

N/A

USD 4.66B
IFFF:LSE iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 0.84B
SAEM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.00 %

N/A

USD 2.92B
SEDM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.00 %

N/A

USD 0.67B
HMEM:LSE HSBC MSCI Emerging Market.. 0.00 % 0.00 %

N/A

USD 2.41B
HMFD:LSE 0.00 % 0.00 %

N/A

N/A
SUES:LSE iShares Sustainable MSCI .. 0.00 % 0.00 %

N/A

USD 3.14B
SUSM:LSE iShares Sustainable MSCI .. 0.00 % 0.00 %

N/A

USD 3.14B
UB30:LSE UBS MSCI Emerging Markets.. 0.00 % 0.00 %

N/A

USD 1.58B
XCX6:LSE Xtrackers MSCI China UCIT.. 0.00 % 0.00 %

N/A

USD 0.91B
XMME:LSE Xtrackers MSCI Emerging M.. 0.00 % 0.00 %

N/A

USD 5.45B
XX25:LSE Xtrackers FTSE China 50 U.. 0.00 % 0.00 %

N/A

USD 0.16B
XX2D:LSE Xtrackers - FTSE China 50.. 0.00 % 0.00 %

N/A

USD 0.16B
KESG 0.00 % 0.00 %

N/A

N/A
EMXF iShares ESG Advanced MSCI.. 0.00 % 0.00 %

N/A

USD 0.08B
VFEA:LSE Vanguard FTSE Emerging Ma.. 0.00 % 0.00 %

N/A

USD 0.55B
EDG2:LSE iShares MSCI EM ESG Enhan.. 0.00 % 0.00 %

N/A

USD 4.47B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.48% 17% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.48% 18% F 8% B-
Trailing 12 Months  
Capital Gain -70.70% 28% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.70% 28% F 13% F
Trailing 5 Years  
Capital Gain -64.39% 63% D 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.39% 62% D 31% F
Average Annual (5 Year Horizon)  
Capital Gain 12.18% 59% D- 59% D-
Dividend Return 12.18% 59% D- 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.57% 53% F 39% F
Risk Adjusted Return 16.55% 67% D+ 51% F
Market Capitalization 7.17B 97% N/A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.